KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $4.4 million.

  • Acadia Pharmaceuticals' Net Cash Flow rose 12301.11% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.6 million, marking a year-over-year increase of 7264.26%. This contributed to the annual value of $134.0 million for FY2024, which is 8153.57% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Net Cash Flow is $4.4 million, which was up 12301.11% from $36.6 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Net Cash Flow's 5-year high stood at $176.1 million during Q1 2023, with a 5-year trough of -$180.6 million in Q2 2023.
  • Its 5-year average for Net Cash Flow is -$3.4 million, with a median of -$12.1 million in 2023.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Net Cash Flow soared by 36679.2% in 2022, and later plummeted by 73351.36% in 2025.
  • Acadia Pharmaceuticals' Net Cash Flow (Quarter) stood at $52.8 million in 2021, then plummeted by 175.74% to -$40.0 million in 2022, then skyrocketed by 326.26% to $90.5 million in 2023, then skyrocketed by 81.82% to $164.5 million in 2024, then crashed by 97.35% to $4.4 million in 2025.
  • Its Net Cash Flow was $4.4 million in Q3 2025, compared to $36.6 million in Q2 2025 and -$101.9 million in Q1 2025.